UK metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.2% during the forecast period. As per the National Health Service, UK, in 2017, 28.7% of adults in England were obese and 35.6% were overweight. Of obese adults, nearly 1 in 8 are morbidly obese (3.6% of all adults). Diabetes is a form of metabolic disorder, which results in an increasing demand for diabetic medications that are used for the treatment of the condition include Metformin (Glucophage, Glumetza, others), Thiazolidinediones (rosiglitazone (Avandia) and pioglitazone (Actos)), and others.  Rosiglitazone (Avandia) is intended for use as an adjunct to exercise and diet to improve glycemic control in adults suffering from type 2 diabetes mellitus. It is a highly potent and selective agonist for the peroxisome proliferator-activated receptor-gamma (PPAR?)-responsive genes that participate in the regulation of fatty acid metabolism. 

UK metabolic disorder therapeutics market is segmented based on type and disease. Based on type, the market is classified into drug therapy, gene therapy, cellular transplantation, enzyme replacement therapy, and others. Drug therapy is being significantly preferred for the treatment of metabolic disorders. Pioglitazone (Actos) and Metformin (Glucophage) are some common metabolic drugs that are used for the treatment of the metabolic syndrome. The increasing development of new drugs is further expected to drive the demand for drug therapy for metabolic disorders. Based on disease, the market is classified into obesity, diabetes, lysosomal storage disease, hypercholesterolemia, and others.

Some prominent players in the market include Bristol-Myers Squibb Co., AbbVie, Inc., Novo Nordisk A/S, Sitryx Pharmaceuticals, and AstraZeneca plc. Partnerships and collaborations are one of the vital strategies adopted by market players. For instance, in March 2020, AstraZeneca plc declared the collaboration with Silence Therapeutics for discovery, development, and commercialization of small interfering RNA (siRNA) therapeutics to treat CVD, respiratory, renal, and metabolic disorders. This multi-target partnership will use the established small interfering RNA (siRNA) platform of Silence to detect and progress liver-based targets and develop new delivery methods to target other tissues including the heart, kidney, and lung. 

Research Methodology

The market study of the UK metabolic disorder therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. UK Metabolic Disorder Therapeutics Market Research and Analysis by Therapy
2. UK Metabolic Disorder Therapeutics Market Research and Analysis by Disease

The Report Covers

• Comprehensive research methodology of the UK metabolic disorder therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK metabolic disorder therapeutics market.
• Insights about market determinants which are stimulating the UK metabolic disorder therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.